Log In
Print this Print this

ASG-22ME (formerly ASG-22M6E)

  Manage Alerts
Collapse Summary General Information
Company Seattle Genetics Inc.
DescriptionAntibody-drug conjugate (ADC) targeting nectin-4
Molecular Target Nectin-4 (PRR4)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner Astellas Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today